Will NICE’s New Medtech Evaluation Plans Hit the Target for Patients and Industry?
The UK’s medical technology industry is raising concerns that the proposed Rules-Based Pathway may be too limited to bring about much-needed change in the evaluation process. One year after its introduction, the industry claims that the UK’s healthtech assessment and adoption processes continue to fall short of meeting the needs of both innovators and patients.
The Rules-Based Pathway was initially mooted as a means to provide clarity on what medtechs could expect from an evaluation. However, the industry now feels that the current proposals are insufficient. The concerns come as the UK’s National Institute for Health and Care Excellence (NICE) continues to develop its medtech evaluation plans.
The industry’s concerns highlight the ongoing challenges faced by medtech innovators in the UK. Despite efforts to improve the evaluation process, the adoption of new health technologies remains slow. The situation underscores the need for a more effective and efficient evaluation pathway that balances the needs of patients, innovators, and the healthcare system.
